Maddalena Donini

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study

Orazio Caffo, Ugo De Giorgi, Lucia Fratino et al. · European Urology · 2014 · 83 citations · Full text

Medicine, Oncology, Urology +12

Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study

Giuseppe Procopio, Giulia Apollonio, Francesco Cognetti et al. · European Urology Oncology · 2019 · 54 citations

Medicine, Oncology, Surgery +15

Impressive Response With Imatinib in a Heavily Pretreated Patient With Metastatic <i>c-KIT</i> Mutated Thymic Carcinoma

Sebastiano Buti, Maddalena Donini, Pietro Sergio et al. · Journal of Clinical Oncology · 2011 · 46 citations · Full text

Medicine, Immunology, Oncology +7

Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer

Orazio Caffo, Donatello Gasparro, Giuseppe Di Lorenzo et al. · European Journal of Cancer · 2020 · 26 citations · Full text

Medicine, Oncology, Urology +17

Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme

Francesca Maines, Orazio Caffo, Ugo De Giorgi et al. · Clinical Genitourinary Cancer · 2015 · 21 citations

Medicine, Oncology, Pharmacology +16